Photo by peterconlan from unsplash
No longer recognised as a single disease entity with a “one size fits all” approach to treatment, asthma is an umbrella diagnosis spanning different endotypes and clinical phenotypes. The discovery… Click to show full abstract
No longer recognised as a single disease entity with a “one size fits all” approach to treatment, asthma is an umbrella diagnosis spanning different endotypes and clinical phenotypes. The discovery of T2 inflammation as a driver in many asthma patients transformed our understanding of this disease and inspired the discovery of targeted biological therapies [1]. T2 inflammation is mediated by cytokines including interleukin (IL)-4, IL-5 and IL-13, which then regulate the production of measurable biomarkers including IgE, blood and sputum eosinophils, and fractional exhaled nitric oxide (FeNO) [2]. There is a need for stable biomarkers of endotype for asthma across the lifecourse to provide earlier precision medicine approaches https://bit.ly/3PAS19i
Journal Title: European Respiratory Journal
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!